Controversial nods came for Urogen’s Zusduri and Astra/Daiichi’s Datroway.
ApexOnco Front Page
Recent articles
Adverse events will be closely watched when full data are reported.
Emilta-L continues to show worse efficacy than a rival ADC discontinued by Pfizer.
Emrelis becomes the first drug for cMet-positive NSCLC, but only for the highest expressers.
Early data with ELVN-001 hold up well against olverembatinib and TERN-701.
IBI3020 beats Chengdu Kanghong's KH815 into clinical trials.
The company deprioritises its lead project, naporafenib, shifting to two Joyo-originated assets.
The group’s point-of-care Car-T push looks to have stalled.
